Senate Majority Leader Harry ReidHarry ReidCommunities struggling with decline of coal can’t wait any longer on RECLAIM Act Week ahead: AT&T-Time Warner merger under scrutiny This week: Government funding deadline looms MORE (D-Nev.) announced an agreement on amendments Wednesday that will finally allow a Food and Drug Administration bill to move forward. The deal should lead to passage of the bill on Thursday, ending several days of uncertainty.

Under the agreement, the Senate will consider 17 amendments to the bill, the Food and Drug Administration Safety and Innovation Act (S. 3187), which reauthorizes a user-fee program for drug companies seeking FDA approval. The Senate will debate amendments until Thursday at 2 p.m. After votes on the amendments, the Senate will vote on the bill itself.

The agreement marks an end to a standstill over which amendments to consider, a problem that has slowed Senate work on several bills throughout the 112th Congress.
"I appreciate everyone's help and it takes everyone's help to get where we are," Reid said on the Senate floor after the deal was reached.

Senate Minority Leader Mitch McConnellMitch McConnellSenate GOP to Obama: Stop issuing new rules Communities struggling with decline of coal can’t wait any longer on RECLAIM Act Juan Williams: McConnell won big by blocking Obama MORE (R-Ky.) said the deal was a "good agreement that allows us to go forward on the FDA bill with appropriate amendments."

Under the agreement, four of the 17 amendments will require 60 votes for passage. One of these, from Sen. John McCainJohn McCainSenate: Act now to save Ukraine A Cabinet position for Petraeus; disciplinary actions for Broadwell after affair Meet Trump’s ‘mad dog’ for the Pentagon MORE (R-Ariz.), would require Health and Human Services Secretary Kathleen SebeliusKathleen SebeliusLeaked email: Podesta pushed Tom Steyer for Obama’s Cabinet Romney: Trump victory 'very possible' Fighting for assisted living facilities MORE to issue regulations allowing the importation of prescription drugs from Canada, within six months after the language becomes law.
Language from Sen. Bernie SandersBernie SandersHouse GOP to unveil short-term funding bill Tuesday Week ahead: AT&T-Time Warner merger under scrutiny This week: Government funding deadline looms MORE (I-Vt.) would take away exclusive drug marketing rights from companies found to be guilty of fraud. An amendment from Sen. Lisa MurkowskiLisa MurkowskiPassing US-Canada preclearance would improve security and economy Overnight Energy: Dakota pipeline standoff heats up Trump's wrong to pick Bannon or Sessions for anything MORE (R-Alaska) would limit the ability of the government to approve genetically modified fish or other marine wildlife. The fourth amendment requiring 60 votes was offered by Sen. Jeff Bingaman (D-N.M.); his language is aimed at ending delays in getting approval of generic drugs.

Among the remaining amendments are two that set up a fight over how much the FDA should be able to regulate dietary supplements. One amendment from Sen. Dick DurbinDick DurbinThis week: Government funding deadline looms Lawmakers eye early exit from Washington Senators crafting bill to limit deportations under Trump MORE (D-Ill.) would require dietary supplement makers to register with the FDA, while the other from Sen. Rand PaulRand PaulGOP rep: Trump has 'extra-constitutional' view of presidency The ignored question: What does the future Republican Party look like? Rand Paul skeptical about Romney as secretary of State MORE (R-Ky.) would prevent the government from taking any action to limit claims that a food supplement has certain mitigating effects against diseases. 

Details on the other amendments that could be voted on follow here, although some of these were expected to be withdrawn.

Sen. Ben CardinBen CardinAide: Trump invited Philippine leader to WH Dem senator: Hold hearing on Russian interference in election Overnight Finance: Questions swirl around Trump's plan for his business | Treasury pick promises major tax cut | White House downplays Carrier deal MORE (D-Md.) -- requiring the FDA to devise a plan to educate people about the risks of various medical products.

Sen. Charles GrassleyChuck GrassleyDrug pricing debate going into hibernation GOP leaders host Trump's top deputies Key Republican wants details on Ohio State attacker MORE (R-Iowa) -- providing protections for the commissioned corps of the public health service.

Sen. Joseph Manchin (D-W.Va.) -- to reclassify the pain reliever hydrocodone under the controlled substances act.

Sen. Rob PortmanRob PortmanGOP debates going big on tax reform Who is Tim Ryan? A closer look at Pelosi’s challenger Battle for the Senate: Top of ticket dominates MORE (R-Ohio) -- requiring the government to establish a system for facilitating the exchange of prescription drug information across state lines.

Sen. Jack ReedJack ReedThis Week in Cybersecurity: Dems press for information on Russian hacks A Cabinet position for Petraeus; disciplinary actions for Broadwell after affair Overnight Cybersecurity: Last-ditch effort to stop expanded hacking powers fails MORE (D-R.I.) -- setting phased-in compliance dates for a rule on sunscreen labeling.

Sen. Tom CoburnTom CoburnWill Trump back women’s museum? Don't roll back ban on earmarks Ryan calls out GOP in anti-poverty fight MORE (R-Okla.) -- setting rules on employee performance awards.

Coburn -- requiring an audit of the drug approval process.

Sen. Richard BurrRichard BurrDems pledge to fight Sessions nomination Battle for the Senate: Top of ticket dominates Shakeup on Senate Intel: Warner becomes top Dem MORE (R-N.C.) -- allowing members of Congress and their staffs to attend certain negotiations between the FDA and the regulated industry. Burr said on the Senate floor after the deal was announced that he would not force a vote on this language.